| ［1］ |
von KL, Svensson Å, Apfelbacher C, et al. Factors that predict remission of infant atopic dermatitis: a systematic review［J］. Acta Derm Venereol, 2015, 95（4）: 389⁃394. DOI: 10.2340/00015555⁃1941.
|
| ［2］ |
Guo Y, Li P, Tang J, et al. Prevalence of Atopic Dermatitis in Chinese Children aged 1⁃7 ys［J］. Sci Rep, 2016, 6: 29751. DOI: 10.1038/srep29751.
|
| ［3］ |
Hajar T, Leshem YA, Hanifin JM, et al. A systematic review of topical corticosteroid withdrawal （"steroid addiction"） in patients with atopic dermatitis and other dermatoses［J］. J Am Acad Dermatol, 2015, 72（3）: 541⁃549.e2. DOI: 10.1016/j.jaad.2014. 11.024.
|
| ［4］ |
Barnes L, Kaya G, Rollason V. Topical corticosteroid⁃induced skin atrophy: a comprehensive review［J］. Drug Saf, 2015, 38（5）: 493⁃509. DOI: 10.1007/s40264⁃015⁃0287⁃7.
|
| ［5］ |
Ma Z, Jiao Z. Mast cells as targets of pimecrolimus［J］. Curr Pharm Des, 2011, 17（34）: 3823⁃3829.
|
| ［6］ |
Prucha H, Schnopp C, Akdis C, et al. Pimecrolimus, a topical calcineurin inhibitor used in the treatment of atopic eczema［J］. Expert Opin Drug MetabToxicol, 2013, 9（11）: 1507⁃1516. DOI: 10.1517/17425255.2013.819343.
|
| ［7］ |
Ho VC, Gupta A, Kaufmann R, et al. Safety and efficacy of nonsteroidpimecrolimus cream 1 in the treatment of atopic dermatitis in infants［J］. J Pediatr, 2003, 142（2）: 155⁃162. DOI: 10.1067/mpd.2003.65.
|
| ［8］ |
Kapp A, Papp K, Bingham A, et al. Long⁃term management of atopic dermatitis in infants with topical pimecrolimus, a nonsteroid anti⁃inflammatory drug［J］. J Allergy ClinImmunol, 2002, 110（2）: 277⁃284. DOI: 10.1067/mai.2002.126500.
|
| ［9］ |
Lee SJ, Woo SI, Ahn SH, et al. Functional interpretation of metabolomics data as a new method for predicting long⁃term side effects: treatment of atopic dermatitis in infants［J］. Sci Rep, 2014, 4: 7408. DOI: 10.1038/srep07408.
|
| ［10］ |
Sigurgeirsson B, Boznanski A, Todd G, et al. Safety and efficacy of pimecrolimus in atopic dermatitis: a 5⁃year randomized trial［J］. Pediatrics, 2015, 135（4）: 597⁃606. DOI: 10.1542/peds.2014⁃1990.
|
| ［11］ |
Luger T, Boguniewicz M, Carr W, et al. Pimecrolimus in atopic dermatitis: consensus on safety and the need to allow use in infants［J］. Pediatr Allergy Immunol, 2015, 26（4）: 306⁃315. DOI: 10.1111/pai.12331.
|
| ［12］ |
Margolis DJ, Abuabara K, Hoffstad OJ, et al. Association between malignancy and topical use of pimecrolimus［J］. JAMA Dermatol, 2015, 151（6）: 594⁃599. DOI: 10.1001/jamadermatol. 2014.4305.
|
| ［13］ |
Cai SC, Li W, Tian EA, et al. Topical calcineurin inhibitors in eczema and cancer association: a cohort study［J］. J Dermatolog Treat, 2016, 27（6）: 531⁃537. DOI: 10.3109/09546634.2016. 1163317.
|
| ［14］ |
Ring J, Barker J, Behrendt H, et al. Review of the potential photo⁃cocarcinogenicity of topical calcineurin inhibitors: position state⁃ment of the European Dermatology Forum［J］. J Eur Acad Dermatol Venereol, 2005, 19（6）: 663⁃671. DOI: 10.1111/j.1468⁃3083.2005.01315.x.
|
| ［15］ |
Pariser D. Topical corticosteroids and topical calcineurin inhibi⁃tors in the treatment of atopic dermatitis: focus on percutaneous absorption［J］. Am J Ther, 2009, 16（3）: 264⁃273. DOI: 10.1097/MJT.0b013e31818a975c.
|
| ［16］ |
Lakhanpaul M, Davies T, Allen BR, et al. Low systemic exposure in infants with atopic dermatitis in a 1⁃year pharmacokinetic study with pimecrolimus cream 1［J］. Exp Dermatol, 2006, 15（2）: 138⁃141. DOI: 10.1111/j.1600⁃0625.2006.00398.x.
|
| ［17］ |
Staab D, Pariser D, Gottlieb AB, et al. Low systemic absorption and good tolerability of pimecrolimus, administered as 1 cream （Elidel） in infants with atopic dermatitis⁃⁃a multicenter, 3⁃week, open⁃label study［J］. Pediatr Dermatol, 2005, 22（5）: 465⁃471. DOI: 10.1111/j.1525⁃1470.2005.00128.x.
|
| ［18］ |
Papp KA, Breuer K, Meurer M, et al. Long⁃term treatment of atopic dermatitis with pimecrolimus cream 1 in infants does not interfere with the development of protective antibodies after vaccination［J］. J Am Acad Dermatol, 2005, 52（2）: 247⁃253. DOI: 10.1016/j.jaad.2004.08.046.
|
| ［19］ |
Paul C, Cork M, Rossi AB, et al. Safety and tolerability of 1 pimecrolimus cream among infants: experience with 1 133 patients treated for up to 2 years［J］. Pediatrics, 2006, 117（1）: e118⁃128. DOI: 10.1542/peds.2005⁃1188.
|
| ［20］ |
Oranges T, Dini V, Romanelli M. Skin physiology of the neonate and infant: clinical implications［J］. Adv Wound Care （New Rochelle）, 2015, 4（10）: 587⁃595. DOI: 10.1089/wound.2015. 0642.
|
